NAMS
NewAmsterdam Pharma Company N.V.
$37.25
+$1.08(+2.99%)
42
Overall
50
Value
45
Tech
31
Quality
Market Cap
$3.95B
Volume
766.26K
52W Range
$14.06 - $42.00
Target Price
$46.92
Company Overview
| Mkt Cap | $3.95B | Price | $37.25 |
| Volume | 766.26K | Change | +2.99% |
| P/E Ratio | -16.3 | Open | $36.37 |
| Revenue | $45.6M | Prev Close | $36.17 |
| Net Income | $-241.6M | 52W Range | $14.06 - $42.00 |
| Div Yield | N/A | Target | $46.92 |
| Overall | 42 | Value | 50 |
| Quality | 31 | Technical | 45 |
No chart data available
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NAMS | $37.25 | +3.0% | 766.26K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get NewAmsterdam Pharma Company N.V. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW